← All stories
Markets
Ananda Developments (LSE:ANA): Is Clinical Evidence Finally Replacing Hype In UK Cannabis Stocks?
Highlights Ananda Developments has progressed its lead cannabidiol candidate for chronic inflammatory pain onto a public clinical trials registry. Later-stage clinical work has been relocated to Australia, where development subsidies materi…
Covered by 1 outlet
All coverage · 1 article